Bronchoscopic Lung Volume Reduction with Endobronchial Valve Implantation in One Patient with Severe Emphysema

Nan Li,Jianxing Qiu,Wei Zhang,Hong Zhang,Xuchu Zhang,Chengli Que,Guangfa Wang

DOI: https://doi.org/10.1378/chest.1388927

IF: 9.6

2012-01-01

Chest

Abstract:SESSION TYPE: Bronchology Global Case Report Posters

What problem does this paper attempt to address?

Therapy Endobronchial Lipoma by APC Resection: A Case Report

fanglei liu,enguo chen,kejing ying

DOI: https://doi.org/10.1378/chest.1381182

IF: 9.6

2012-01-01

Chest

Abstract:SESSION TYPE: Airway Student/Resident Case Report Posters
Advances in bronchoscopic lung volume reduction using endobronchial valves

孙康,潘蕾,金发光

DOI: https://doi.org/10.3760/cma.j.cn131368-20200410-00274

2020-01-01

Abstract:Because of hyperinflation, patients with severe emphysema can result in hypoxia symptoms and even respiratory failure.Severe emphysema is an irreversible progressive chronic respiratory disease in which drug treatment has poor effects.After continuous exploration, lung volume reduction surgery and endoscopic lung volume reduction got a great development.Bronchoscopic lung volume reduction using endobronchial valves is currently the only reversible endoscopic lung volume reduction, which meets the criteria of clinical application.It has the same benefit as surgical lung volume reduction, but it is less invasive and has less complications and lower mortality.It has been recommended by the GOLD and UK/NICE guidelines as a treatment option for patients with severe emphysema.Endobronchial valves can cause target lung lobe atelectasis, reduce hyperinflation, and ultimately improve pulmonary function and clinical symptoms.The success of the operation and the maximum benefit of the patients depend on the accurate selection of patient and the target lobe and negative collateral ventilation between the target lobe and the adjacent lobe.Either heterogeneous or homogeneous emphysema has been proven to benefit from this procedure.Prediction and active management of postoperative complications can minimize the risk of surgical complications.
Progresses in the endobronchial lung volume reduction with one-way valve

GaoYadong,Li Dai,Ge Huang,Jiong Yang

DOI: https://doi.org/10.3760/cma.j.issn.1673-436X.2016.09.018

2016-01-01

Abstract:Chronic obstructive pulmonary disease (COPD) is a common airway inflammatory disease characterized by high morbidity and mortality.The standard pharmaceutical therapy for COPD is the inhaled bronchodilators combined with inhaled glucocorticoids,in order to reducing the frequency of acute exacerbation and the decline rate of lung function.In the past decades,endobronchial lung volume reduction (ELVR) has been introduced to the treatment of advanced emphysema.It has been proved to be effective to improve the life quality and lung function of strictly selected patients with heterogeneous emphysema.Different procedures have been developed for ELVR,including airway bypass fenestration,one-way valve implantation,lung volume reduction coils,and bronchoseopic thermal vapor ablation.These procedures are different in the action mechanisms,effectiveness,indications,contraindications,complications and reversibility.Among them,valve implantation is the most wide-spread procedure around the world.Recent years,many clinical studies and observations have been conducted to better understanding the action mechanisms,indications and contraindications,assessment before and after the procedure and the prevention of complication.Here we reviewed these publications and try to clarify the importance of these studies.
Bronchoscopic Lung Volume Reduction for Pulmonary Emphysema: Preliminary Experience with Endobronchial Occluder.

Liqiang Song,Feng Zhao,Xinyu Ti,Weiqiang Chen,Gaowen Wang,Changgui Wu,Yan Li

DOI: https://doi.org/10.4187/respcare.02218

2013-01-01

Respiratory Care

Abstract:OBJECTIVE: To describe the self-expanding endobronchial occluder, as utilized in bronchoscopic lung volume reduction, with a 36 month follow-up procedure. METHODS: Twenty-three subjects with severe emphysema were recruited and underwent flexible bronchoscopic placement of self-expanding endobronchial occluders. Outcomes were assessed at 1 week, 1-month, 3-, 6-, 12-, 24-, and 36-month intervals. Feasibility, safety, and efficacy were analyzed by means of pulmonary function testing, 6-min walk test, dyspnea score, BODE (body mass index, air-flow obstruction, dyspnea, and exercise capacity) index, and St George's Respiratory Questionnaire. RESULTS: Fifty-eight self-expanding endobronchial occluders were implanted into 23 lobes previously selected. No displacement was found during the follow-up. Five subjects experienced postoperative complications of cough, and 6 subjects had lobar pneumonia, which were not located in any of the blocked segments. The FEV1 in 18 subjects was improved by > 15%, compared with baselines (P < .001), and the mean first efficacy time and maximal efficacy time were 5.65 +/- 1.51 months and 6.35 +/- 3.08 months, respectively. No significant changes were observed in FVC or the ratio of residual volume to TLC. The 6-min walk distance, dyspnea score, and St George's Respiratory Questionnaire total score were improved in 22 subjects over a 24-month period, and a minority of subjects continued to improve through to the end of the study. Mean baseline BODE index had improved during follow-up, but not at the study's conclusion. CONCLUSIONS: This preliminary study demonstrates early significant improvements in pulmonary function, 6-min walk distance, dyspnea score, BODE index, and quality of life after placement of the self-expanding endobronchial occluder in bronchoscopic lung volume reduction. Its placement also proved both easy and safe. However, the initial improvements were maintained long-term for only a minority of subjects.
Advances and Applications of Bronchoscopic Lung Volume Reduction.

Yang Xiao,Suisheng Zhao,Yi Hu,Xiaowu Shi,Li Tan

2015-01-01

Abstract:Lung volume reduction surgery usually gives rise to high postoperative morbidity and impedes its further application. Recently, a plethora of bronchoscopic lung volume reduction techniques such as one-way endobronchial valves, biological sealants, thermal vapor ablation, airway bypass stents and lung volume reduction coils have been extensively used in emphysema treatment. The current data for bronchoscopic lung volume reduction although not conclusive enough do present multiple safer ways compared with conventional surgery with few serious complications, lower cost and shortened hospital care. The bronchoscopic lung volume reduction will undergo continuous development as constant randomized trials are performed to prove its full efficacy.
Endobronchial Valve Therapy for Patients with Advanced Emphysema. A Report from a Tertiary Care Center in China

Hang Yu,Zhen Yang,Minghui Zhu,Zhixin Liang,Wei Zhao,Qiang Zhu,Liang-an Chen

DOI: https://doi.org/10.15537/smj.2022.43.12.20220527

2022-01-01

Saudi Medical Journal

Abstract:Objectives: To assess the efficiency and safety of endobronchial valve (EBV) treatment in Chinese patients. Methods: A retrospective analysis was performed in patients with chronic obstructive pulmonary disease who underwent EBV implantation in our hospital between October 2010 and January 2017. All patients were confirmed with no collateral ventilation (CV-) or with low airflow (LF) in the treated lobe. Pulmonary function parameters, the 6-minute walk distance (6MWD), the modified Medical Research Council (mMRC), as well as adverse events in the follow-up period were recorded. Results: Thirty-eight advanced emphysema patients received EBV implantation. Significant improvements were found in forced expiratory volume in 1 second (FEV1)(FEV1: +0.12 L), 6MWD (+64.9 m), and mMRC (-0.5 points). A total of 55.3% and 65.8% of subjects met the score for the minimal clinically important difference in FEV1 and 6MWD, respectively. FEV1 improved more significantly in the CV-group than in the LF group. Pneumothorax or death did not occur during the follow-up period. Conclusion: Endobronchial valve treatment in patients with advanced emphysema and CV-provides clinically meaningful benefits with a low incidence of pneumothorax. The efficiency and safety of EBV therapy are acceptable in China.
Lung Volume Reduction in Pulmonary Emphysema

Justin L Garner,Pallav L Shah,Justin L. Garner,Pallav L. Shah

DOI: https://doi.org/10.1055/s-0040-1702192

2020-05-20

Seminars in Respiratory and Critical Care Medicine

Abstract:Abstract Severe emphysema with hyperinflation presents a therapeutic challenge. Inhaled medication has limited efficacy in individuals with mechanical constraints to the respiratory pump and impaired gas exchange. Lung volume reduction surgery (LVRS) reestablishes some semblance of normal physiology, resecting grossly expanded severely diseased tissue to restore the function of compromised relatively healthy lung, and has been shown to significantly improve exercise capacity, quality of life, and survival, especially in individuals with upper-lobe predominant emphysema and low-baseline exercise capacity, albeit with higher early morbidity and mortality. Bronchoscopic lung volume reduction achieved by deflating nonfunctioning parts of the lung is promoted as a less invasive and safer approach. Endobronchial valve implantation has demonstrated comparable outcomes to LVRS in selected individuals and has recently received approvals by the National Institute of Clinical Excellence in the United Kingdom and the Food and Drug Administration in the United States of America. Endobronchial coils are proving a viable treatment option in severe hyperinflation in the presence of collateral ventilation in selected cases of homogeneous disease. Modalities including vapor and sealant are delivered using a segmental strategy preserving healthier tissue within the same target lobe-efficacy and safety-data are, however, limited. This article will review the data supporting these novel technologies.

respiratory system,critical care medicine
Advances And Applications Of Bronchoscopic Lung Volume Reduction

Yang Xiao,Su Zhao,Yi Hu,Xiaowu Shi,Li Tan

2015-01-01

Abstract:Lung volume reduction surgery usually gives rise to high postoperative morbidity and impedes its further application. Recently, a plethora of bronchoscopic lung volume reduction techniques such as one-way endobronchial valves, biological sealants, thermal vapor ablation, airway bypass stents and lung volume reduction coils have been extensively used in emphysema treatment. The current data for bronchoscopic lung volume reduction although not conclusive enough do present multiple safer ways compared with conventional surgery with few serious complications, lower cost and shortened hospital care. The bronchoscopic lung volume reduction will undergo continuous development as constant randomized trials are performed to prove its full efficacy.
Late Breaking Abstract - Preliminary Safety and Efficacy of PulmValve Endobronchial Valve in Treating Severe Heterogeneous Emphysema: A First-in-Human Study

Li,S.-Y.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa4360

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Background: Endobronchial valves is a recognized treatment for emphysema. Key challenges were the technical complexity of upper lobe implantation and the number of valves required. PulmValve (MedTecX, Shanghai, China), a novel endobronchial valve aims to address these issues. Objective: This study evaluated the preliminary safety and efficacy of PulmValve in patients with severe emphysema. Method: This First-in-Human, prospective study enrolled patients with severe heterogeneous emphysema in the first affiliated hospital of Guangzhou medical university between January and December 2023 for PulmValve implantation. The primary endpoint was safety, with feasibility and efficacy as secondary endpoints. Results: Five patients (aged 58–77 years) with severe heterogeneous emphysema and no collateral ventilation (fissure integrity >90%), were included. Baseline FEV1 was 0.926±0.312 L, 6-minute walk test (6MWT) was 305.60±31.80 m, and SGRQ score was 52.35±14.50. Totally 6 PulmValves were successfully implanted in 5 patients with a mean procedure time of 4.047±2.127 minutes. One patient experienced pneumothorax within 3 days, and another had AECOPD within 4 weeks, both patients fully recovered after appropriate treatment. After 3 months, FEV1 increased by 0.132±0.103 L (p=0.045), 6MWT improved by 34.06±43.07 m (p=0.152), and SGRQ score decreased by 13.14±10.23 points (p=0.045). Conclusion: The application of PulmValve can treat heterogeneous emphysema by implanting only 1-2 endobronchial valves in a relatively short procedure time, demonstrating preliminary safety, feasibility, and efficacy. Larger, long-term studies are needed to confirm these promising results.

respiratory system
Bronchoscopic lung volume reduction with one-way endobronchial valve in treatment of elderly refractory pneumothorax patients:three cases report

Xiaojie Qu,Yuqing Chen,Qiang Li,Min Zhang,Xin Zhou

DOI: https://doi.org/10.3760/cma.j.issn.1673-436X.2016.18.013

2016-01-01

Abstract:Objective To observe the clinical effect and adverse reactions of bronchoscopic lung volume reduction (BLVR) with Zephyr one-way endobronchial valve (EBV) in treatment of elderly refractory pneumothorax.Methods Three elderly male patients with refractory pneumothorax were enrolled.All these patients were treated with thoracic closed drainage for more than two weeks (chest drainage tube diameter ≥ 1 6F).Flexible bronchoscope examination was operated under the condition of topical anesthesia.The target lung lobes were assessed by Chartis system intraoperatively.Results 2-5 EBV was placed in lobar or segmental bronchi to completely isolate the target lung lobe respectively in three patients.Postoperatively,all patients survived and had no severe compliations,chest drainage tube was pulled up 7-10 days later.Conclusions BLVR with EBV can be operated in the elderly under the condition of topical anesthesia.Many advantages are found such as minimal trauma,simple operation and good safety.Chartis system is the good standard of evaluating collateral ventilation between target lung lobe and nearby lobe.
Research progress of bronchoscopic lung volume reduction in treating end-stage emphysema

Ruilin Sun,Faguang Jin,Hua Jiang,Yonghong Xie,Wei Liu,Qi An

DOI: https://doi.org/10.3760/cma.j.issn.1673-436X.2014.22.011

2014-01-01

Abstract:Bronchoscopic lung volume reduction is a minimally invasive procedure based on the lung reduction principle,the aim is to make the far end tracheal air dispersion to pulmonary capillary circulation and the emphysematous pulmonary atelectatic,the so-called "medical resiction” dead space lung tissue in order to reduce the lung capacity.Because of the less invasive,less risk,lower cost of treatment,the wider indications compared with lung volume reduction surgery,it may have great potential clinical application to provide more choices in the treatment of end-stage emphysema.
Impact of Bronchoscopic Lung Volume Reduction with Valves on the Pulmonary Gas Exchange

Jane Winantea,Katharina Stiehl,Ruediger Karpf-Wissel,Faustina Funke,Hubertus Hautzel,Birte Schwarz,Heinz Steveling,Christian Taube,Filiz Oezkan,Kaid Darwiche

DOI: https://doi.org/10.3390/jcm13082354

IF: 3.9

2024-04-19

Journal of Clinical Medicine

Abstract:Introduction: Bronchoscopic lung volume reduction (BLVR) with endobronchial valves has been shown to be a safe and effective treatment for patients with severe lung emphysema. Previous studies have reported a benefit in pulmonary function, exercise capacity, and quality of life after BLVR-treatment. The effect of BLVR with valves on the pulmonary gas exchange and its association with clinical outcomes has not been analyzed to date. The primary goal of this study was to investigate the impact of BLVR on the pulmonary gas exchange and the impact of the target lobe selection in patients with discordant target lobes in high-resolution computed tomography (HRCT) scan and perfusion scan on the pulmonary gas exchange and clinical outcomes. Methods: In this single-center study, we retrospectively analyzed pulmonary function tests, 6-min-walk-tests, HRCT scans, perfusion scans, and blood gas analyses in 77 patients over the course of 6 months following BLVR treatment. Results: We observed that complete lobar occlusion with bronchoscopic valves leads to a transient impairment of pulmonary gas exchange. Despite this, an overall positive clinical outcome could be shown in patients treated with endobronchial valves. If the target lobe selection based on HRCT and perfusion scans is discrepant, a selection based on the HRCT scan tends to be associated with a better outcome than a selection based on the perfusion scan. Conclusions: Complete lobar occlusion with bronchoscopic valves leads to a transient impairment of pulmonary gas exchange but nevertheless results in an overall positive clinical outcome.

medicine, general & internal
First In Vivo Experiment with PulmValve Endobronchial Valve: Feasibility, Efficiency, and Safety

Jingwei Liu,Difei Chen,Yanhui Yu,Yu Deng,Ruijin Lu,Jing Zhang,Shiyue Li

DOI: https://doi.org/10.1159/000538269

2024-03-26

Respiration

Abstract:Introduction: Endoscopic Lung Volume Reduction (ELVR) with endobronchial valves has been widely recognized for treating hyperinflation in advanced COPD and emphysema patients. The main challenges include the technical complexity of upper lobe implantation and the number of endobronchial valves required. These issues might be addressed by placing larger-diameter valves in the lobar bronchus. This study evaluated the feasibility, efficiency, and safety of the new valve PulmValve (model PV-13) in porcine models. Methods: Six PV-13 valves were bronchoscopically implanted into the caudal lobe bronchus of six healthy pigs. The procedure time, valve deployment, and removability were recorded. Follow-up examinations included blood tests, chest CT scans, and bronchoscopy at 30 minutes, 14 days, 28 days, and 84 days post-procedure, with necropsy and pathological evaluations after the final follow-up examination. Results: The successful in vivo deployment and removal of PV-13 valves was established, with a median procedure time of 6.5 minutes. The distal lung volume reduction was evident at 30 minutes post-operation and was persistently monitored on day 84. No migration or malfunction of any PV-13 valves was detected, but a mild angle deviation was found in three cases. Coughing was observed in four pigs within the first seven days, and localized granulation tissue was observed in all pigs. No cases of pneumothorax, diffuse pneumonia, or hemoptysis were detected. Conclusions: In this study, we report the successful implantation and removal of a new valve PulmValve in a short operation time. Complete lobar atelectasis was induced without device migration, malfunction, or severe complications. Further studies are warranted to evaluate the long-term, sustained effects, and potential benefits in human patients.

respiratory system
Bronchoscopic Lung Volume Reduction: A Review

Shreya Podder,Marium Khan,Zane Sink,Steven Verga,Jonathan S. Kurman,Elizabeth Malsin

DOI: https://doi.org/10.1055/s-0044-1787876

2024-07-19

Seminars in Respiratory and Critical Care Medicine

Abstract:Bronchoscopic lung volume reduction (BLVR) is an established treatment modality for the management of advanced chronic obstructive pulmonary disease complicated by severe emphysema and hyperinflation refractory to other therapies. BLVR aims to reduce hyperinflation and residual volume, thereby improving pulmonary function, symptom control, and quality of life. Multiple distinct devices and technologies, including endobronchial coils, thermal vapor ablation, bio-lung volume reduction, and airway bypass stenting, have been developed to achieve lung volume reduction with varying degrees of accessibility and evidence. The most promising BLVR treatment modality to date has been the placement of one-way endobronchial valves (EBVs), with more than 25,000 cases performed worldwide. Identifying symptomatic patients who would benefit from BLVR is challenging and can be time and resource intensive, and candidacy may be limited by physiologic parameters. Additional new technologies may be able to improve the identification and evaluation of candidates as well as increase the portion of evaluated patients who ultimately qualify for BLVR. In this review, we aim to provide historical context to BLVR, summarize the available evidence regarding its use, discuss potential complications, and provide readers with a clear guide to patient selection and referral for BLVR, with a focus on EBV placement. In addition, we will highlight potential future directions for the field. Article published online: 18 July 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

respiratory system,critical care medicine
Changes in Ventilation and Perfusion Following Lower Lobe Endoscopic Lung Volume Reduction (ELVR) with Endobronchial Valves in Severe COPD.

Li Yang,Kelvin Hsu,Jonathan P. Williamson,Matthew J. Peters,Kevin Ho-Shon,Alvin J. Ing

DOI: https://doi.org/10.1111/crj.13031

2019-01-01

Abstract:We have previously reported significant improvements in ventilation and perfusion (VQ) and V/Q matching in the contralateral lung, especially the non‐targeted lower zone in patients with severe COPD following upper lobe ELVR with endobronchial valves. However, V/Q changes after lower lobe ELVR have not been described.
Study on Transbronchoscopic Interventional Treatment with One-Way Valve Stent in Severe Emphysema

Na He

2009-01-01

Abstract:Objective To evaluate the technique of implanting and withdrawing the domestic-made stents in the study on clinical application of bronchoscopic interventional lung volume reduction. Methods From May 2006 to March 2008,8 cases with severe emphyseme,male 7,female 1,aged 43 - 70 years,were implanted flexible stents under general anesthesia. Among them total or partial withdrawal were performed in 2 patients. Results Four to six stents per patient were implanted into the obstructed upper-lobe branchial segments unilaterally with operation time (124.00 ± 63.26) min. All patients could walk in 2 hours after operation,their dyspnea relieved obviously. No major life-threatening complications were found. Lower-lobe pneumonia developed in 1 patient and 1 patient occurred acute episode of chronic obstructive pulmonary disease (COPD). Pneumonia occurred in 2 patients during following-up 6 - 24 months. Stents withdrawal were performed in 2 patients due to the distal end pneumonia. Conclusion The technique of stents implantation and withdrawal with one-way value stent lung volume reduction under general anesthesia is convenient and comparatively safe.
Staged Bilateral Single-Port Thoracoscopic Lung Volume Reduction Surgery: A Report of 11 Cases

Miao Zhang,Heng Wang,Xuefeng Pan,Wenbin Wu,Hui Zhang

DOI: https://doi.org/10.3892/etm.2016.3702

IF: 2.7

2016-01-01

Experimental and Therapeutic Medicine

Abstract:The aim of the present study was to investigate the feasibility and efficacy of staged bilateral single-port thoracoscopic lung volume reduction surgery (LVRS) for patients with chronic obstructive pulmonary emphysema (COPE). Eleven male patients with a mean age of 60.27±12.11 years with bilateral COPE and bullae were admitted to the Department of Thoracic Surgery, Xuzhou Central Hospital from January 2013 to June 2014. The patients underwent staged bilateral single-port thoracoscopic LVRS. The hyperinflated bullae were resected using endoscopic staplers (Endo-GIA), followed by continuous suture and biological glue for reinforcement of the margin. In addition, pulmonary function, blood gas assay, 6-min walk distance (6MWD) and life quality evaluated by a short form 36-item health survey questionnaire (SF-36) were recorded before and after LVRS, respectively. All the patients survived after surgery. The chest tube drainage time was 9.09±1.31 days and postoperative hospital stay was 15.73±2.75 days, with 5 cases of persistent air leakage and 7 cases of pulmonary infection which were finally cured. The patients were followed up for 3 to 12 months, and the pulmonary function, partial pressure of oxygen (pO2), 6MWD and life quality after unilateral or bilateral LVRS were improved compared to these parameters before surgery. However, there was no significant difference between unilateral and bilateral LVRS in terms of life quality. In conclusion, staged bilateral single-port thoracoscopic LVRS may improve the short-term life quality of patients with COPE.
Pulmonary Resection Combined with Volume Reduction for Patients with Lung Cancer and Severe Emphysema

D Jiaan,J Gening,Z Xiao

DOI: https://doi.org/10.1016/s0169-5002(00)80483-3

2000-01-01

Abstract:Objective: To evaluate the effects of lobectomy combined with lung volume reduction for patient with early stage NSCLC and severe emphysema. Methods: All 3 patients were male. Age ranged from 60 to 64 years. Histological type of the lung cancer was squamous carcinoma in 2 and adenocarcinoma in 1. The tumor located in right upper lobe in 2 and left lower lobe in 1. Preoperative dyspnea index was grade 2 in 1 and grade 3 in 2. Mean FEV 1 was 0.90 l(36.3%), mean PaO 2 was 73.5 mm?Hg and the mean 6 minute walk was 287.7 m. Operative procedures included lobectomy in 2 and wedge resection in 1. Lung volume reduction surgery was performed in all patients (20%～30%) contralateral lung tissue were resected. Results: There was no major complication. All patients recovered well. After operation, the symptoms such as palpitation, dyspnea was improved significantly. 3 patients were followed up 1 to 6 months, FEV 1, PaO 2, 6 minute walk and dyspnea index were increased by 40%, 20.5 mm?Hg, 46.7% and 1 grade, respectively. Conclusion: For selective early stage NSCLC patients with severe emphysema, lobectomy combined with LVRS is an effective method. It can provide significant functional benefit and symptomatic relief. It widens the operative indication for lung cancer.
Clinical Outcomes and Quantitative CT Analysis after Bronchoscopic Lung Volume Reduction Using Valves for Advanced Emphysema

Fangfang Guo,Junfang Huang,Yan Hu,Jianxing Qiu,Hong Zhang,Wei Zhang,Yuan Cheng,Jiping Liao,Guangfa Wang

DOI: https://doi.org/10.21037/jtd-21-1734

2022-01-01

Journal of Thoracic Disease

Abstract:Background Bronchoscopic lung volume reduction (BLVR) using Zephyr endobronchial valve (EBV) and intrabronchial valve (IBV) has been shown to improve lung function and exercise capacity in severe emphysema. However, changes in airway structures and whether these are related to the clinical improvements remain unclear. Methods A retrospective study was performed on patients treated with BLVR. We compared changes in 2nd-, 3rd-, and 4th-generation bronchial structures after therapy, including wall thickness (WT), percentage of wall thickness (WT%), intraluminal area (LA), wall area (WA), and WA%. Responder and non-responder subgroup analysis according to minimum clinically important difference (MCID) which was defined as an improvement of 15% in forced expiratory volume in 1 s (FEV1) and 26 m in 6 min walk distance (6MWD) was conducted. Results Of the 19 patients, 11 were treated with EBV and 8 with IBV. In ipsilateral non-target lobes, WT% decreased significantly in 3rd-generation bronchi at 1 month, 3, and 6 months, as well as their WA% at 1 month and 6 months. Non-responders, who were unable to achieve MCID, showed no consistent bronchial wall changes. And their LA of 3rd-generation bronchi decreased especially at 1 month. After BLVR, the target lobe volume decreased significantly until 12 months of follow-up. The volume of ipsilateral lobes could increase correspondingly and achieve the best improvements at 6 months. The contralateral lung volume showed slight amelioration but there was no statistical significance. Conclusions Both airway structures and lung volumes showed changes after BLVR. The 3rd- and 4th-bronchial walls tend to be thinner, which were consistent with clinical improvements. Further studies are needed to prove this conclusion and find detect potential mechanics.
Research progress on two types of lung volume reduction

Weifeng LI,Zhenrong ZHANG,Deruo LIU

DOI: https://doi.org/10.7507/1007-4848.201606037

2017-01-01

Abstract:Emphysema is a chronic progressive disease characterized by abnormal terminal bronchioles.Patients in end-stage have limited treatment.Lung volume reduction surgery(LVRS) is to remove the non-functional emphysematous lung tissue with the aim of palliating symptoms in selected patient with severe emphysema.It provides a new therapeutic method for emphysema.When LVRS is widely accepted after 1990s,a large number of institutions carried out the researches on surgical approaches,perioperative mortality,long-term efficacy and complications.Its targeted beneficial patients and surgical safety had been confirmed too.Bronchoscopic lung volume reduction (BLVR) successfully carried out on the basis of the development of LVRS and bronchoscopy.This article reviews the surgical approaches,safety and efficacy of LVRS and BLVR in patients with emphysema.

Bronchoscopic Lung Volume Reduction with Endobronchial Valve Implantation in One Patient with Severe Emphysema

Therapy Endobronchial Lipoma by APC Resection: A Case Report

Advances in bronchoscopic lung volume reduction using endobronchial valves

Progresses in the endobronchial lung volume reduction with one-way valve

Bronchoscopic Lung Volume Reduction for Pulmonary Emphysema: Preliminary Experience with Endobronchial Occluder.

Advances and Applications of Bronchoscopic Lung Volume Reduction.

Endobronchial Valve Therapy for Patients with Advanced Emphysema. A Report from a Tertiary Care Center in China

Lung Volume Reduction in Pulmonary Emphysema

Advances And Applications Of Bronchoscopic Lung Volume Reduction

Late Breaking Abstract - Preliminary Safety and Efficacy of PulmValve Endobronchial Valve in Treating Severe Heterogeneous Emphysema: A First-in-Human Study

Bronchoscopic lung volume reduction with one-way endobronchial valve in treatment of elderly refractory pneumothorax patients:three cases report

Research progress of bronchoscopic lung volume reduction in treating end-stage emphysema

Impact of Bronchoscopic Lung Volume Reduction with Valves on the Pulmonary Gas Exchange

First In Vivo Experiment with PulmValve Endobronchial Valve: Feasibility, Efficiency, and Safety

Bronchoscopic Lung Volume Reduction: A Review

Changes in Ventilation and Perfusion Following Lower Lobe Endoscopic Lung Volume Reduction (ELVR) with Endobronchial Valves in Severe COPD.

Study on Transbronchoscopic Interventional Treatment with One-Way Valve Stent in Severe Emphysema

Staged Bilateral Single-Port Thoracoscopic Lung Volume Reduction Surgery: A Report of 11 Cases

Pulmonary Resection Combined with Volume Reduction for Patients with Lung Cancer and Severe Emphysema

Clinical Outcomes and Quantitative CT Analysis after Bronchoscopic Lung Volume Reduction Using Valves for Advanced Emphysema

Research progress on two types of lung volume reduction